Use of HBsAg-positive donors in liver transplantation: An ILTS-EASL-AASLD multisociety survey.

Autor:	Vinaixa C; Department of Digestive Diseases, Hepatology, and Liver Transplantation, Hospital Universitario y Politécnico La Fe, Valencia, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain., DiMaira T; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain., Russo FP; Department of Surgery, Oncology and Gastroenterology, Gastroenterology and Multivisceral Transplant Unit, Azienda Ospedale-Università Padova, Padova, Italy., Goldberg D; Division of Digestive Health and Liver Diseases, University of Miller, Miller School of Medicine, Miami, Florida, USA., Mazzola A; Unité Médicale de Transplantation Hépatique, Service d'hépato-gastroentérologie. Hôpital Pitié-Salpêtrière, Sorbonne Université, Paris, France., Walabh P; Department of Paediatrics and Child Health, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.; Paediatric Gastroenterology, Hepatology, and Nutrition, Charlotte Maxeke Johannesburg Academic Hospital, University of Witwatersrand, Johannesburg, South Africa., Price J; Division of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco, University of San Francisco, California, USA., Sagal S; Hepatology and Liver Transplant, Centre of Liver and Biliary Sciences, Centre of Gastroenterology, Hepatology, and Endoscopy, Max Saket Hospital, New Delhi, India., Kirchner V; Division of Abdominal Transplantation, Department of Surgery, Stanford University, California, USA., Shaker T; Division of Abdominal Transplantation, Methodist Transplant Institute- San Antonio, Texas Transplant Institute, San Antonio, Texas, USA., Krag A; Department of Clinical Research, University of Southern Denmark and Head of Hepatology, Odense University Hospital, University of Southern Denmark, Odense, Denmark., Pruett T; Department of Solid Organ Transplantation, University of Minnesota, Minnesota, USA., Coilly A; Centre Hepato-Biliaire, Paul Brousse Hospital, Paris-Saclay University, Villejuif, France., Terrault N; Department of Gastrointestinal Liver Diseases, University of Southern California, Keck School of Medicine, Los Angeles, California, USA., Berenguer M; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.; Department of Medicine, School of Medicine of Valencia, Spain.
Jazyk:	angličtina
Zdroj:	Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society [Liver Transpl] 2024 Nov 01; Vol. 30 (11), pp. 1116-1122. Date of Electronic Publication: 2024 Jul 17.
DOI:	10.1097/LVT.0000000000000432
Abstrakt:	The gap between organ supply and demand in liver transplantation remains large in most parts of the world. One strategy to increase the donor pool is to use grafts infected with HCV, HBV, and/or HIV viruses. We aimed to explore the current use of HBsAg-positive liver grafts worldwide. A prospective cross-sectional web-based survey was designed, with a total of 28 queries, assessing national and local regulations, center experience, and center-specific experience related to the topic, and sent to all members of International Liver Transplantation Society, European Association for the Study of the Liver, and American Association for the Study of the Liver, and promoted on social media. A total of 135 liver transplant centers answered the survey: 38% from WHO European Regions, 39% from American regions, and 9.7% from South-East Asian regions. Most of the participating centers (67.3%) had been performing liver transplantation for over 15 years, with a mean of 66.5 liver transplants per year, and 54% also performed living-donor liver transplants. HBV-related disease was the indication for liver transplantation in an average of 15% of all liver transplantation cases. Regarding national and/or regional regulations, 40% of the centers reported that the use of HBsAg-positive donors was permitted, and an additional 20% could use them under special circumstances. Thirty-two centers (31%) had previously used HBsAg-positive donors. Among these centers, 62.5% conducted living-donor liver transplants and showed an increased inclination toward the use of HBsAg-positive grafts in centers with elevated waitlist mortality. HBsAg-positive donors are underutilized worldwide. The use of HBsAg-positive liver grafts could help to increase the donor pool, particularly in highly endemic areas. (Copyright © 2024 American Association for the Study of Liver Diseases.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu